Protocol Page


	Study ID (Protocol Number)
	AI443-014


	STUDY LOCATIONS*
	Alamo Medical Research San Antonio, TX 78215 Recruiting	Mercy Medical Center, Inc. Baltimore, MD 21202 Recruiting
	Local Institution Lutherville, MD 21093 Not yet recruiting	Metropolitan Research Fairfax, VA 22031 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
	STUDY OVERVIEW
	The purpose of this study is to estimate the rate of sustained virologic response (SVR) SVR12, where SVR12 is defined as HCV RNA < LOQ (detectable or undetectable) 12 weeks post-treatment in Genotype 1 & Genotype 4 treatment naive patients, and Genotype (GT1) infected patients who are prior null responders to pegIFN/ribavirin

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.